Tags

Type your tag names separated by a space and hit enter

Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
J Eur Acad Dermatol Venereol. 2009 Mar; 23(3):277-82.JE

Abstract

BACKGROUND

Effective, fast-acting and safe therapies are needed for long-term maintenance treatment of psoriasis. In October 2005, infliximab was approved for the treatment of moderate-to-severe plaque psoriasis, but long-term data are limited.

OBJECTIVE

To evaluate the effectiveness of infliximab, used in combination with methotrexate or azathioprine, in maintaining clinical benefit in patients with moderate-to-severe psoriasis.

METHODS

The medical charts of 23 patients treated with infliximab from August 2001 to February 2007 were retrospectively reviewed. Most patients received either infliximab 3 mg/kg (17 of 23) or 5 mg/kg (1 of 23) in combination with methotrexate, while 5 of 23 patients received infliximab 5 mg/kg in combination with azathioprine. Psoriasis Area Severity Index (PASI) score and adverse events were recorded at every infliximab infusion visit at the hospital.

RESULTS

Patient data were available for a minimum of 4 weeks and up to 5 years and 5 months. At week 14, 91.3% achieved PASI 50, 69.6% achieved PASI 75, and 39.1% achieved PASI 90. Only two patients discontinued therapy due to loss of response: one after 15 months and one after 3 years. All other patients displayed a good clinical response (> or = PASI 50) and were still receiving this regimen at last observation. Combination regimens of infliximab with methotrexate or azathioprine were well tolerated, and only one patient discontinued therapy because of an adverse event (lung embolism) after two infusions with infliximab.

CONCLUSIONS

Long-term (> 1 year) maintenance therapy of infliximab combined with methotrexate or azathioprine is effective and well tolerated for moderate-to-severe plaque-type psoriasis.

Authors+Show Affiliations

Department of Dermatology, St. Olavs. Hospital, Trondheim University Hospital, Trondheim, Norway. mdalak@online.noNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19207642

Citation

Dalaker, M, and J H. Bonesrønning. "Long-term Maintenance Treatment of Moderate-to-severe Plaque Psoriasis With Infliximab in Combination With Methotrexate or Azathioprine in a Retrospective Cohort." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 23, no. 3, 2009, pp. 277-82.
Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277-82.
Dalaker, M., & Bonesrønning, J. H. (2009). Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. Journal of the European Academy of Dermatology and Venereology : JEADV, 23(3), 277-82. https://doi.org/10.1111/j.1468-3083.2008.03039.x
Dalaker M, Bonesrønning JH. Long-term Maintenance Treatment of Moderate-to-severe Plaque Psoriasis With Infliximab in Combination With Methotrexate or Azathioprine in a Retrospective Cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277-82. PubMed PMID: 19207642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. AU - Dalaker,M, AU - Bonesrønning,J H, Y1 - 2008/12/19/ PY - 2009/2/12/entrez PY - 2009/2/12/pubmed PY - 2009/8/14/medline SP - 277 EP - 82 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 23 IS - 3 N2 - BACKGROUND: Effective, fast-acting and safe therapies are needed for long-term maintenance treatment of psoriasis. In October 2005, infliximab was approved for the treatment of moderate-to-severe plaque psoriasis, but long-term data are limited. OBJECTIVE: To evaluate the effectiveness of infliximab, used in combination with methotrexate or azathioprine, in maintaining clinical benefit in patients with moderate-to-severe psoriasis. METHODS: The medical charts of 23 patients treated with infliximab from August 2001 to February 2007 were retrospectively reviewed. Most patients received either infliximab 3 mg/kg (17 of 23) or 5 mg/kg (1 of 23) in combination with methotrexate, while 5 of 23 patients received infliximab 5 mg/kg in combination with azathioprine. Psoriasis Area Severity Index (PASI) score and adverse events were recorded at every infliximab infusion visit at the hospital. RESULTS: Patient data were available for a minimum of 4 weeks and up to 5 years and 5 months. At week 14, 91.3% achieved PASI 50, 69.6% achieved PASI 75, and 39.1% achieved PASI 90. Only two patients discontinued therapy due to loss of response: one after 15 months and one after 3 years. All other patients displayed a good clinical response (> or = PASI 50) and were still receiving this regimen at last observation. Combination regimens of infliximab with methotrexate or azathioprine were well tolerated, and only one patient discontinued therapy because of an adverse event (lung embolism) after two infusions with infliximab. CONCLUSIONS: Long-term (> 1 year) maintenance therapy of infliximab combined with methotrexate or azathioprine is effective and well tolerated for moderate-to-severe plaque-type psoriasis. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/19207642/Long_term_maintenance_treatment_of_moderate_to_severe_plaque_psoriasis_with_infliximab_in_combination_with_methotrexate_or_azathioprine_in_a_retrospective_cohort_ L2 - https://doi.org/10.1111/j.1468-3083.2008.03039.x DB - PRIME DP - Unbound Medicine ER -